Ceftriaxone Dosing for Community-Acquired Pneumonia
For adults with community-acquired pneumonia and normal renal function, use ceftriaxone 1-2 grams IV once daily, with the specific dose determined by disease severity and patient characteristics.
Standard Dosing Recommendations
Non-ICU Hospitalized Patients
For patients admitted to a medical ward with CAP, ceftriaxone 1 gram IV once daily is appropriate 1. The IDSA/ATS guidelines recommend ceftriaxone (without specifying dose) as a preferred β-lactam, combined with either azithromycin or a fluoroquinolone 2.
Recent high-quality evidence supports 1 gram daily dosing:
- A 2023 Israeli retrospective cohort study of nearly 4,000 patients found no difference in 30-day mortality between 1 g and 2 g daily (14.7% vs 16.0%, p=0.24), with 1 g associated with significantly lower C. difficile infection rates (0.2% vs 0.6%, p=0.03) and shorter hospital stays 3
- A 2019 systematic review and meta-analysis confirmed that 1 g daily is as effective as higher doses for CAP (OR 1.02,95% CI 0.91-1.14) 4
- Pharmacokinetic studies demonstrate that 1 g daily achieves adequate target attainment (>90% probability) for pathogens with MIC ≤2 mg/L in non-ICU patients 5
ICU Patients with Severe CAP
For ICU patients, use ceftriaxone 2 grams IV once daily 2. The higher dose is justified by:
- A 2025 Japanese nationwide study of 471,694 patients showing that 2 g daily reduced 30-day mortality in mechanically ventilated patients (17.2% vs 20.4%, risk difference -3.2%, p=0.006) 6
- Greater pathogen burden and severity of illness requiring higher drug exposure
- The IDSA/ATS guidelines specifically recommend ceftriaxone as a preferred β-lactam for severe CAP requiring ICU admission 2
Dosing Adjustments
Renal Function Considerations
No dose adjustment is necessary for renal impairment when using standard doses up to 2 grams daily 7. The FDA label explicitly states: "No dosage adjustment is necessary for patients with impairment of renal or hepatic function" 7. However:
- For patients with eGFR >60 mL/min/1.73 m², consider 1 gram every 12 hours rather than once daily to maintain adequate trough concentrations, particularly if targeting resistant organisms 8
- For patients with eGFR ≤60 mL/min/1.73 m², 1 gram every 24 hours is sufficient 8
Risk Factors for Resistant Organisms
Increase to 2 grams daily when risk factors for drug-resistant pathogens are present, including:
- Pseudomonas risk: Switch to an antipseudomonal β-lactam (piperacillin-tazobactam, cefepime, imipenem, or meropenem) rather than increasing ceftriaxone dose 2
- MRSA risk: Add vancomycin or linezolid to ceftriaxone 2
- MSSA pneumonia: Ceftriaxone 1 g daily performs poorly against methicillin-susceptible Staphylococcus aureus (53% early clinical failure rate), requiring either dose escalation to 2-4 grams daily or alternative therapy 9
Administration Details
- Infusion time: Administer over 30 minutes for adults 7
- Combination therapy: Always combine with either azithromycin or a respiratory fluoroquinolone for empirical CAP treatment 2
- Duration: Minimum 5 days, continue until afebrile for 48-72 hours with no more than one sign of clinical instability 2
Critical Caveats
Do not use ceftriaxone 1 gram daily for MSSA pneumonia - this dose shows unacceptably high failure rates (53%) and requires either 2-4 grams daily or alternative antibiotics 9. The FDA label recommends 2-4 grams daily for serious staphylococcal infections 7.
For patients with augmented renal clearance (eGFR >90 mL/min/1.73 m²), once-daily dosing may be inadequate for organisms with MIC ≥4 mg/L, necessitating either twice-daily dosing or alternative therapy 5, 8.